<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40342">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581202</url>
  </required_header>
  <id_info>
    <org_study_id>P15-452</org_study_id>
    <nct_id>NCT02581202</nct_id>
  </id_info>
  <brief_title>The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation</brief_title>
  <acronym>SIMPLE</acronym>
  <official_title>ProSpective, MultI-Center, Observational PrograM to Assess the Effectiveness of Dual TheraPy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Routine Clinical Settings of the Russian Federation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to assess the virologic effectiveness of dual therapy (lopinavir/ ritonavir
      (LPV/r) + lamivudine (3TC)) in treatment-experienced human immunodeficiency virus 1 (HIV-1)
      infected participants with an undetectable plasma HIV-1 (ribonucleic acid) RNA level (for at
      least 6 months) at the 48 week time point of treatment in the routine clinical settings of
      the Russian Federation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants on dual therapy (LPV/r + 3TC) with undetectable HIV-1 RNA level at week 48</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants on dual therapy (LPV/r + 3TC) with undetectable HIV-1 RNA level at week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of the absolute values of HIV-1- RNA viral loader</measure>
    <time_frame>Baseline, Week 24, and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the absolute values of CD4+ T-cell counts</measure>
    <time_frame>Baseline, Week 24, and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who develop resistance to protease inhibitors</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in absolute values of anthropometric measurements</measure>
    <time_frame>Baseline, Week 24, and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the absolute values of metabolic parameters</measure>
    <time_frame>Baseline, Week 24, and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who develop resistance to Lamivudine</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">216</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>HIV-1 infected participants</arm_group_label>
    <description>Treatment-experienced HIV-1 infected participants with an undetectable plasma HIV-1 RNA level</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lopinavir/ritonavir</intervention_name>
    <description>tablet</description>
    <arm_group_label>HIV-1 infected participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>tablet</description>
    <arm_group_label>HIV-1 infected participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-1 infected participants on any triple HAART with undetectable plasma HIV-1 RNA level
        for at least 6 months (two consequently plasma HIV-1 RNA levels) transferred as medically
        appropriate to LPV/r + 3TC in the routine clinical settings.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years and older (male and female).

          2. HIV-1 infected patients on any triple HAART with plasma HIV-1 RNA level &lt;50 copies/mL
             for at least 6 months (two consequently plasma HIV-1 RNA levels) transferred as
             medically appropriate to LPV/r + 3TC as decided by the physician in the routine
             clinical settings. OR HIV-1 infected patients who were switched on the dual therapy
             (LPV/r + 3TC) no more than 60 days ago.

          3. Cumulative HAART experience at least 6 months.

          4. Authorization (Consent) for Use/Disclosure of Data signed by the patient.

        Exclusion Criteria:

          1. Contraindications to lopinavir/ritonavir and lamivudine

          2. Previous participation in this program
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrey Strugovschikov, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145685</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454038</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145687</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454038</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145697</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145689</name>
      <address>
        <city>Irkutsk</city>
        <zip>664035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145686</name>
      <address>
        <city>Kaliningrad</city>
        <zip>236006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145684</name>
      <address>
        <city>Kazan</city>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145683</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145692</name>
      <address>
        <city>Moscow</city>
        <zip>105275</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145693</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145695</name>
      <address>
        <city>Orenburg</city>
        <zip>460035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145691</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145694</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145690</name>
      <address>
        <city>Ufa</city>
        <zip>450077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 20, 2017</lastchanged_date>
  <firstreceived_date>October 19, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antiretroviral therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
